文献速递肿瘤 PET/CT

是否使用对比剂?评估肝胆对比剂在肝脏FDG-PET/MR中诊断准确性的前瞻性研究

To contrast or not to contrast? Evaluating the diagnostic accuracy of hepatobiliary contrast agents in liver FDG-PET/MR: a prospective study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-05-09

这项前瞻性单中心诊断准确性研究纳入60例经组织学确诊的腹部恶性肿瘤伴恶性肝病变患者,评估单独FDG-PET、非增强PET/MR及增强PET/MR(含或不含肝胆期)的诊断效能。含肝胆期的增强FDG-PET/MR诊断准确性最高(97%),敏感性97.8%,特异性95.2%;加入肝胆期显著提高特异性(75.6%至95.2%,p=0.013)并能检出更小病灶(中位大小7 mm vs 19 mm,p=0.00017)。

要点

  • 含肝胆期的增强FDG-PET/MR诊断准确性达97%,敏感性97.8%,特异性95.2%。
  • 加入肝胆期使特异性从75.6%提高至95.2%(p=0.013)。
  • 含肝胆期可检出更小病灶(中位大小7 mm vs 19 mm,p=0.00017)。

核心结论

  • 纳入肝胆对比剂可显著提升FDG-PET/MR对肝脏恶性肿瘤的诊断效能,尤其在检出较小或边界不清病灶方面。
  • 作者认为这些发现支持将肝胆期整合入PET/MR工作流程以优化肝病灶检出与分期。

研究设计与样本

  • 前瞻性单中心诊断准确性研究,纳入60例经组织学确诊的腹部恶性肿瘤伴恶性肝病变患者。
  • 每例患者接受全身FDG-PET/MR,包括上腹部专用成像:非增强、增强不含肝胆期、增强含肝胆期。
  • 由三名盲法放射科医师独立阅片并以共识方式评估。
  • 参考标准为组织病理学或随访影像。
  • 计算敏感性、特异性、阳性预测值、阴性预测值及诊断准确性,采用Fisher精确检验和Mann-Whitney U检验进行统计比较。

主要发现

  • 共识别134个恶性肝病变(38个原发肿瘤,96个转移灶)。
  • 含肝胆期的增强FDG-PET/MR诊断准确性最高(97%),敏感性97.8%,特异性95.2%。
  • 非增强FDG-PET/MR准确性67%,敏感性78%,特异性44%。
  • 单独FDG-PET准确性最低(52%)。
  • 加入肝胆期显著提高特异性(75.6%至95.2%,p=0.013),并能检出更小病灶(中位大小7 mm vs 19 mm,p=0.00017)。

关键数值与推荐

  • 含肝胆期的增强FDG-PET/MR:诊断准确性97%,敏感性97.8%,特异性95.2%。
  • 非增强FDG-PET/MR:准确性67%,敏感性78%,特异性44%。
  • 单独FDG-PET:准确性52%。
  • 加入肝胆期前后特异性分别为75.6%和95.2%(p=0.013)。
  • 含肝胆期检出的病灶中位大小7 mm,不含肝胆期为19 mm(p=0.00017)。

临床怎么用

  • 作者认为这些发现支持将肝胆期整合入PET/MR工作流程以优化肝病灶检出与分期。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The role of hepatobiliary contrast-enhanced imaging in the evaluation of liver malignancies in FDG-PET/MR remains underexplored. The aim of this study was to assess the diagnostic performance of stand-alone FDG-PET, non-contrast-enhanced (NCE) PET/MR, and contrast-enhanced (CE) PET/MR with and without hepatobiliary phase (HBP). METHODS: This prospective, single-center diagnostic accuracy study enrolled 60 patients with histologically confirmed abdominal malignancies and malignant liver lesions. Each patient underwent whole-body FDG-PET/MR, including dedicated upper abdominal imaging with NCE, CE without HBP, and CE with HBP. Three blinded radiologists independently evaluated the images in consensus. The reference standard was histopathology or follow-up imaging. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic accuracy were calculated. Fisher's exact test and Mann-Whitney U test were used for statistical comparisons. RESULTS: A total of 134 malignant liver lesions (38 primary tumors, 96 metastases) were identified. CE FDG-PET/MR with HBP achieved the highest diagnostic accuracy (97%), sensitivity (97.8%), and specificity (95.2%). NCE FDG-PET/MR had an accuracy of 67%, sensitivity of 78%, and specificity of 44%, while stand-alone FDG-PET had the lowest accuracy (52%). The addition of HBP significantly improved specificity (75.6-95.2%, p = 0.013) and enabled detection of smaller lesions (median size 7 mm vs. 19 mm, p = 0.00017). CONCLUSION: The inclusion of hepatobiliary contrast significantly enhances the diagnostic performance of FDG-PET/MR for liver malignancies, particularly in detecting small or poorly defined lesions. These findings support the integration of HBP into PET/MR workflows to optimize liver lesion detection and staging. CLINICAL TRIAL NUMBER: Not applicable.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Asmundo L, Furtado F, Delaney F, et al. To contrast or not to contrast? Evaluating the diagnostic accuracy of hepatobiliary contrast agents in liver FDG-PET/MR: a prospective study. Eur J Nucl Med Mol Imaging. 2025. PMID: 40343495. doi:10.1007/s00259-025-07333-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。